Contact
Subscribe
Contact
Subscribe

MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study

Date : November 15, 2016

MaaT Pharma announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study.

 

MaaT Pharma ODYSSEE Study focuses in prevention of dysbiosis complications with autologous fecal microbiota transplantation in Acute Myeloid Leukemia patients undergoing intensive treatment.

 

Lyon (France), November 15th, 2016 – MaaT Pharma, the French pioneer company that develops innovative autologous fecal microbiota transfer based treatments for serious complications in Acute Myeloid Leukemia, Bone and Joint Infections with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company’s Phase 1b study in the prevention of dysbiosis complications with autologous fecal microbiota transfer (AFMT) in Acute Myeloid Leukemia (AML) and the DSMB confirms that no safety issue occurs during the course of the trial and that enrollment will continue as planned until completion.

 

A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. As per study protocol, the DSMB meets at least 3 times during the trial, first after the inclusion of 3 to 5 patients to review the safety data of the ODYSSEE trial and subsequently issues recommendations on the conduct of the study.

 

AML are rare cancers, but potentially fatal in the adults. MaaT Pharma proposes using AFMT to AML patients aged 18 to 75 treated with intensive chemotherapy and antibiotics, therapeutics, which are known to deeply impact the gut microbial composition and to have severe clinical consequences. The purpose of AFMT is to restore the balance of the intestinal microbiome and thereby eradicate treatment-induced multi-drug resistant bacteria (MDRB), infection-related complications, as well as scarring of the gastrointestinal tract.

About MaaT Pharma

Founded at the end of 2014 and based in Lyon (France), MaaT Pharma (Microbiota as a Therapy) is a microbiome–based pharmaceutical company revolutionizing and shaping individualized therapies to treat serious diseases linked to dysbiosis (gut microbiota imbalances). MaaT Pharma is currently developing its first candidate using its proprietary Autologous Fecal Microbiota Transfer Platform for patients suffering from leukemia, bone and joint infections, as these harsh treatments provoke dysbiosis. MaaT Pharma’s revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies.

For more information: https://www.maatpharma.com
Follow us on Twitter: @MaaT_Pharma
Follow us on LinkedIn: http://www.linkedin.com/company/maat-pharma

Previous Post

MaaT Pharma Unveils its First GMP-Compliant Platform

Next Post

Hervé Affagard, MaaT Pharma CEO and co-founder receives « Trophée de l’Entrepreneur en Santé »

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at MaaT Pharma. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson’s Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company’s scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of Xervyteg® in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

Linkedin-in

CEO and co-founder

Hervé Affagard

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA

Linkedin-in Twitter
MaaT Pharma in the News